Focus on Rehabilitation, Exercise and Surgical Coronary Revascularization

Size: px
Start display at page:

Download "Focus on Rehabilitation, Exercise and Surgical Coronary Revascularization"

Transcription

1 Focus on Rehabilitation, Exercise and Surgical Coronary Revascularization

2 Sam Haddad, MD Kenneth O Reilly, MD

3 Disclosure of Commercial or Pharma Support NTD

4 Learning Objectives At the conclusion of this workshop, participants will be able to: Review the potential role of Surgical intervention Exercise and rehabilitation as heart failure management and treatment options

5 Surgical Coronary Revascularization

6 Case 1 69 year old male admitted with a diagnosis of HF Unwell x 3 months, progressive SOBOE and orthopnea Denies chest discomfort at any stage Past history HTN Diabetes diet only Former smoker Was treated medically after ACS 2 years ago Initial assessment: BP 120/92, HR 90 bpm (regular), obvious volume overload NT-BNP 4200 pg/ml, troponin I negative ECG: sinus rhythm, Q waves leads II,III, AVF, QRS duration 140 msec

7 Case 1 Echocardiogram performed: LVEF ~25%, global hypokinesis Mild MR RVSP ~ 45 mmhg Course in hospital over 7 days Diuresed 7 kg with IV furosemide, at dry weight Started on ramipril 5mg/d, and carvedilol 6.25 mg bid Ambulatory, wondering what we are going to do??

8

9 Case 1 - What would you like to do next? A. Coronary angiogram B. Myocardial perfusion imaging (persantine sestamibi) C. Cardiac MRI D. Referral to EP for ICD and or CRT

10 Back to Case 1 Angiogram reveals multivessel coronary disease Occluded RCA 90% mid LAD lesion 70% OM1 and 90% OM2 lesions (medium size) Surgical colleague reviews the films: Technically graftable with good distal target vessels Serum creatinine stable at 140 mmol/l

11

12 Case 1- Your recommended course of action? A. Discharge home with a plan for titrated medical therapy only until angina occurs B. Present the patient to CV surgical colleagues to consider surgical revascularization C. Refer to interventional colleague for multivessel PCI D. Referral for ICD/CRT

13 Prognostic significance of ischemic cardiomyopathy >1200 patients with invasive evaluation for cardiomyopathy over 15 years Ischemic etiology is also an independent predictor of mortality in risk models: Seattle Heart Failure Model (SHFM) Heart Failure Survival Score (HFSS) Levy et al, Circulation 2006 Aaronson et al, Circulation 1997 Felker et al, N Engl J Med 2000

14 Surgical Treatment for Ischemic Heart Failure where s the evidence? Individual patient level meta-analysis of 7 trials 2600 patients enrolled CABG associated with mortality reduction 39% at 5 years, 17% at 10 years No interaction with LV dysfunction and mortality reduction but higher absolute benefits seen in high risk subgroups Yusuf et al, Lancet 2004

15 Surgical Treatment for Ischemic Heart Failure where s the evidence? In these early studies: 90% had angina 80% had normal LVEF 10% had arterial conduits Medical therapy = digoxin and diuretics Need to assess the benefits of revascularization in contemporary patients with ischemic cardiomypathy Yusuf et al, Lancet 2004

16 Current Era: Surgical Treatment for Ischemic Heart failure (STICH) Randomized non-blinded study of surgical revascularization: Included patients with LVEF <35% and CAD suitable for revascularization Hypothesis 1: CABG + medical rx superior to medical rx alone Hypothesis 2: CABG + SVR superior to CABG alone in patients undergoing revascularization with anterior wall akinesis/dyskinesis Velazquez et al, J Thorac and Cardiovasc Surg

17 STICH Hypothesis 1: Primary outcome 1212 patients randomized to CABG vs medical therapy Patients with recent MI, major illness, significant L Main disease and severe angina excluded No difference in all cause mortality seen at median 56 months follow-up 17% of patients in medical therapy arm crossed over to surgical arm

18 STICH Hypothesis 1: secondary outcomes CABG associated with reduction in cardiovascular death and combined outcome of death or cardiovascular hospitalization CABG also associated with 30% relative reduction in mortality in on-treatment analysis (accounting for patients crossing over within 1 st year of study)

19 Recommendations - Revascularization Procedures Assessment for Coronary Disease We recommend that coronary angiography be: a)performed in patients with heart failure with ischemic symptoms, who are likely to be good candidates for revascularization. b)considered in patients with systolic heart failure (LVEF < 35%) at risk of coronary artery disease, irrespective of angina, who may be good candidates for revascularization. Strong Recommendation Moderate Quality Evidence Strong Recommendation Low Quality Evidence

20 Recommendations - Revascularization Procedures Surgical Revascularization for Patients with IHD and HF We recommend consideration of coronary artery bypass surgery for patients with chronic ischemic cardiomyopathy, LVEF < 35%, graftable coronary arteries and who are otherwise suitable candidates for surgery, irrespective of the presence of angina in order to improve quality of life, cardiovascular death and hospitalization. Strong Recommendation Moderate Quality Evidence

21 Recommendations - Revascularization Procedures Disease Management, Referral and Peri-operative Care We recommend that performance of coronary revascularization procedures in patients with chronic heart failure and reduced LV ejection fraction should be undertaken with a medicalsurgical team approach with experience and expertise in high risk interventions. Strong Recommendation Low Quality Evidence Values and Preferences: This recommendation reflects the panel preferences that high risk revascularization is likely to best occur in higher volume centres with significant experience, known outcomes, and similar to participating in clinical trials involving high-risk coronary revascularization. Practical Tip: Assessment for advanced heart failure therapies by an appropriate team should be performed prior to revascularization in any patient with advanced heart failure

22 Exercise Training and Heart Failure

23 Case A 74 year old man with ischemic cardiomyopathy LVEF 33% on echo, mildly dilated LV, MR 1/4 Treatments Candesartan 32mg od, bisoprolol 10 mg od, spironolactone 25 mg od, furosemide 20 mg od ICD for primary prevention since 2003 Stable NHYA II, also limited by bilateral hip pain (OA) Recent mibi shows no ischemia but an orthopedic surgeon refused to operate on his hips because of his cardiac condition

24

25 Regarding exercise in this patient... A. He left ventricular ejection fraction is too poor to exercise B. He comorbidities are contra-indications to cardiac rehabilitation C. He should be referred for cardiac rehabilitation D. He should not exercise as he has a defibrillator E. He should be reassured and encouraged to purchase an elliptical trainer

26 Change in NYHA Class & Kansas City Cardiomyopathy Questionnaire (KCCQ) Score in HFACTION Study NYHA Class KCCQ Score p = 0.03 Percent of Patients Change in KCCQ total score at three months Improved Unchanged Worse Usual Care Exercise Training * P<0.001 compared to baseline O Connor CM et al, JAMA 2009 Flynn et al JAMA 2009

27 Potential Mechanisms by Which Exercise Training Improves Outcomes Organ System/Tissue Improve Central Transport and Regional Blood Flow Autonomic Nervous System Skeletal Muscle Peripheral vasculature Response to Exercise Training in cardiac output; in peak VO 2 ; reverse chronotropic incompetence; regional blood flow heart rate variability; plasma norepinephrine (rest) aerobic enzymes; mitochondria size/density; capillary density; relative type I fibers vasculature reactivity Effect on Mortality and Morbidity peak VO 2 survival; hospitalization HRV arrhythmia survival, hospitalization plasma NE survival muscle composition QOL hospitalization coronary blood flow Ischemia and MI survival, hospitalization

28 HF ACTION Study Design Chronic heart failure, NYHA Class II-IV, LVEF 35%, optimal HF medical therapy, capable of exercising Pre-randomization CPX and ECHO Randomization 1:1 (Stratified by center and HF etiology) Usual Care Whellan DJ. Am Heart J N = 2331 Median Follow-up 2.5 years Exercise Training Supervised exercise (36 sessions) 3d, 30 min 60-70% HRR Home exercise (months: 3-30) 5d, 40 min 60-70% HRR

29 All-Cause Mortality or All-Cause Hospitalization * Adjusted for prognostic factors: duration of CPX; LVEF; Beck Depression score; history A Fib or A Flutter; HF etiology O Connor CM et al, JAMA 2009

30 Recommendations - Rehabilitation and Exercise in HF Exercise Training in Patients with Heart Failure We recommend that all patients with stable New York Heart Association class I-III symptoms be considered for enrolment in a supervised tailored exercise training program, in order to improve exercise tolerance and quality of life. Strong Recommendation Moderate Quality Evidence Values and Preferences: This recommendation places a high value on improvements in non fatal outcomes and recognizes that not all patients will be able to participate in a structured exercise training program due to patient preferences or availability of resources.

31 Recommendations - Rehabilitation and Exercise in HF Exercise Training in Patients with Heart Failure We recommend that an assessment of clinical status by a clinician experienced in the management of heart failure patients be completed prior to considering an exercise training program. Strong Recommendation Low Quality Evidence Values and Preferences: This recommendation places a high value on clinician s assessment of both the clinical stability of a patient and their appropriateness to start exercise, recognizing that most patients will be eligible to participate.

32 How much exercise should you tell the patient to perform? A. Whatever they feel like because it really doesn t matter. B. Low intensity exercise so the heart is not stressed. C. Moderate-intensity continuous exercise (walking/swimming). D. 4. Should be involved only in strength/weight training.

33 Practical Tips Rehabilitation and Exercise in HF with an ICD Exercise Prescription and Exercise Modalities in HF 1. Exercise training is safe and not associated with an increased risk of ICD therapy. 2. The maximal target HR should be at least 20 beats below the ICD intervention heart rate to avoid inappropriate ICD shocks. 3. For patients with ICD, the devices can be programmed with sinus tachycardia discriminators turned on and patients should be encouraged to monitor HR with a portable device.

34 Practical Tip Rehabilitation and Exercise in HF Exercise Prescription and Exercise Modalities in HF Strength Training 1. For strength training, the use of light (5-10 lbs) free weights for repetitions 2 to 3 times per week may improve muscle tone and strength.

35 Back to Case 1 This man actually underwent hip replacement by another surgeon after a PET scan showed no ischemia and no significant viability (IMAGE-HF study 1A Ongoing) Of note, he had incessant VT under Hawaii blue skies (cruise) in October 2012 (ablated in Honolulu) - without loss of consciousness Left hip replacement in January 2013 Swimming 4 times a week in April 2013 Right hip replacement December , NYHA class I

36

CLINCIAL APPLICATION OF GUIDELINES IN HEART FAILURE

CLINCIAL APPLICATION OF GUIDELINES IN HEART FAILURE CLINCIAL APPLICATION OF GUIDELINES IN HEART FAILURE SSC Journée d Automne 25 novembre 2010 Dr. Charles Seydoux, spéc. FMH en médecine interne et en cardiologie, Lausanne Dr. Claudia Bösch, Oberärztin Herzinsuffizienz

More information

Rational use of imaging for viability evaluation

Rational use of imaging for viability evaluation EUROECHO and other imaging modalities 2011 Rational use of imaging for viability evaluation Luc A. Pierard, MD, PhD, FESC, FACC Professor of Medicine Head, Department of Cardiology, CHU Liège, Belgium

More information

Cardiac Viability Testing A Clinical Perspective Annual Cardiac Imaging Symposium. Lisa M Mielniczuk MD FRCPC University of Ottawa Heart Institute

Cardiac Viability Testing A Clinical Perspective Annual Cardiac Imaging Symposium. Lisa M Mielniczuk MD FRCPC University of Ottawa Heart Institute Cardiac Viability Testing A Clinical Perspective Annual Cardiac Imaging Symposium Lisa M Mielniczuk MD FRCPC University of Ottawa Heart Institute 62 year old male Anterior STEMI late presentation, occluded

More information

Revascularization In HFrEF: Are We Close To The Truth. Ali Almasood

Revascularization In HFrEF: Are We Close To The Truth. Ali Almasood Revascularization In HFrEF: Are We Close To The Truth Ali Almasood HF epidemic 1-2% of the population have HF At least one-half have heart failure with reduced ejection fraction (HF- REF) The most common

More information

Case Summary. Workshop Overview. Mr. M

Case Summary. Workshop Overview. Mr. M 9:00 10:30 Workshop Overview Mr. M Who is this document primarily intended to reach? What is the format? How soon should I see a newly referred heart failure patient? How often should my heart failure

More information

Stress ECG is still Viable in Suleiman M Kharabsheh, MD, FACC Consultant Invasive Cardiologist KFHI KFSHRC-Riyadh

Stress ECG is still Viable in Suleiman M Kharabsheh, MD, FACC Consultant Invasive Cardiologist KFHI KFSHRC-Riyadh Stress ECG is still Viable in 2016 Suleiman M Kharabsheh, MD, FACC Consultant Invasive Cardiologist KFHI KFSHRC-Riyadh Stress ECG Do we still need stress ECG with all the advances we have in the CV field?

More information

Ventricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center

Ventricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac

More information

was admitted to the Cardiology Service at the from Y /M /D to Y / M / D under the care of Dr..

was admitted to the Cardiology Service at the from Y /M /D to Y / M / D under the care of Dr.. Patient: was admitted to the Cardiology Service at the from Y /M /D to Y / M / D under the care of Dr.. Discharge Diagnoses include: q CAD-CCS Class: m 0 m 1 m 2 m 3 m 4 q Unstable angina q Non STEMI (non-st

More information

Stable Angina: Indication for revascularization and best medical therapy

Stable Angina: Indication for revascularization and best medical therapy Stable Angina: Indication for revascularization and best medical therapy Cardiology Basics and Updated Guideline 2018 Chang-Hwan Yoon, MD/PhD Cardiovascular Center, Department of Internal Medicine Bundang

More information

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine

More information

Heart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France

Heart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France Heart Failure Guillaume Jondeau Hôpital Bichat, Paris, France Epidemiology Importance of PEF Europe I-PREFER study. Abstract: 2835 Prevalence of HF Preserved LV systolic Function older (65 vs 62 y, p

More information

Revascularization for Patients with HFrEF: CABG and PCI and the Concept of Myocardial Viability

Revascularization for Patients with HFrEF: CABG and PCI and the Concept of Myocardial Viability Revascularization for Patients with HFrEF: CABG and PCI and the Concept of Myocardial Viability 22nd Annual Heart Failure 2018: an Update on Therapy April 2018 Eric J. Velazquez, MD, FACP, FACC, FASE,

More information

A patient with decompensated HF

A patient with decompensated HF A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,

More information

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect

More information

Cardiac Rehabilitation for Heart Failure Patients. Jia Shen MD, MPH Assistant Professor of Medicine UC San Diego Health System

Cardiac Rehabilitation for Heart Failure Patients. Jia Shen MD, MPH Assistant Professor of Medicine UC San Diego Health System Cardiac Rehabilitation for Heart Failure Patients Jia Shen MD, MPH Assistant Professor of Medicine UC San Diego Health System Disclosures There are no conflict of interests related to this presentation.

More information

All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER

All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)

More information

Heart Failure Update. Bibiana Cujec MD May 2015

Heart Failure Update. Bibiana Cujec MD May 2015 Heart Failure Update Bibiana Cujec MD May 2015 Disclosures Participation in clinical trial GUIDE IT (BNP in management of HF) Plan Review of new trials/ccs guidelines Management of heart failure: cases

More information

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital

More information

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor 76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class

More information

March yr. old male, newspaper writer, with worsening dyspnea /orthopnea past few months

March yr. old male, newspaper writer, with worsening dyspnea /orthopnea past few months Case 1 March 2016 59 yr. old male, newspaper writer, with worsening dyspnea /orthopnea past few months PMH diabetes, celiac disease Reports chest discomfort, positional coughing and pedal edema last 10

More information

Surgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011

Surgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011 Surgery and device intervention for the elderly with heart failure: assessing the need Devices and Technology for heart failure in 2011 Assessing cardiovascular function / prognosis (in the elderly): composite

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age

More information

Difficult Data Definitions and Scenario s

Difficult Data Definitions and Scenario s Difficult Data Definitions and Scenario s Presenter Disclosure Information Cornelia Anderson BSN, RN To following relationships exist related to this presentation: No Disclosures Objectives Discuss key

More information

2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much?

2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much? 2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much? Dr. Shelley Zieroth University of Manitoba @ShelleyZieroth @CanHFSociety Disclosures Consulting/Advisory Board: Amgen, Astra

More information

Coronary Revascularization in Patients witj Severe LV Dysfunction.: Is the concept of viability still viable?

Coronary Revascularization in Patients witj Severe LV Dysfunction.: Is the concept of viability still viable? Coronary Revascularization in Patients witj Severe LV Dysfunction.: Implications of the STICH trial Is the concept of viability still viable? Banff 2016 3041435-1 Prognosis of Patients With LV Dysfunction

More information

Coronary interventions

Coronary interventions Controversial issues in the management of ischemic heart failure Coronary interventions Maciej Lesiak Department of Cardiology, University Hospital in Poznan none DECLARATION OF CONFLICT OF INTEREST CHF

More information

1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and

1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and 1 The clinical syndrome of heart failure in adults is commonly associated with the etiologies of ischemic and non-ischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, hypertensive heart disease,

More information

Value of Cardiac Rehabilitation for Improving Patient Outcomes

Value of Cardiac Rehabilitation for Improving Patient Outcomes Value of Cardiac Rehabilitation for Improving Patient Outcomes Pam R. Taub MD, FACC Director of Step Family Cardiac Wellness and Rehabilitation Center Associate Professor of Medicine UC San Diego Health

More information

J. Schwitter, MD, FESC Section of Cardiology

J. Schwitter, MD, FESC Section of Cardiology J. Schwitter, MD, FESC Section of Cardiology CMR Center of the CHUV University Hospital Lausanne - CHUV Switzerland Centre de RM Cardiaque J. Schwitter, MD, FESC Section of Cardiology CMR Center of the

More information

Abnormal, Autoquant Adenosine Myocardial Perfusion Heart Imaging. ID: GOLD Date: Age: 46 Sex: M John Doe Phone (310)

Abnormal, Autoquant Adenosine Myocardial Perfusion Heart Imaging. ID: GOLD Date: Age: 46 Sex: M John Doe Phone (310) Background: Reason: preoperative assessment of CAD, Shortness of Breath Symptom: atypical chest pain Risk factors: hypertension Under influence: a beta blocker Medications: digoxin Height: 66 in. Weight:

More information

CHRONIC CAD DIAGNOSIS

CHRONIC CAD DIAGNOSIS CHRONIC CAD DIAGNOSIS Chest Pain Evaluation 1. Approach to diagnosis of CAD 2. Classification of chest pain 3. Pre-test likelihood CAD 4. Algorithm for chest pain evaluation in women 5. Indications for

More information

Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018

Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018 Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management

More information

Management of High-Risk CAD : Surgeons Perspective

Management of High-Risk CAD : Surgeons Perspective Management of High-Risk CAD : Surgeons Perspective Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan Conflict : Cardiac Surgeon! High Risk CABG 77 year old with prior large anterior

More information

Who does not need a primary preventive ICD?

Who does not need a primary preventive ICD? Who does not need a primary preventive ICD? Hildegard Tanner, Bern Universitätsklinik für Kardiologie Disclosure of potential conflicts of interest Travel grants for educational purposes from: Biosense

More information

Management Strategies for Advanced Heart Failure

Management Strategies for Advanced Heart Failure Management Strategies for Advanced Heart Failure Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation St Vincent Heart Indianapolis, IN USA President American College of Cardiology

More information

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,

More information

Quality Payment Program: Cardiology Specialty Measure Set

Quality Payment Program: Cardiology Specialty Measure Set Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for

More information

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER: ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM General Instructions: The Heart Failure Hospital Record Abstraction Form is completed for all heart failure-eligible cohort hospitalizations. Refer to

More information

CCS/CAIC/CSCS Position Statement on Revascularization Multi-vessel CAD. Teo et al, Canadian Journal of Cardiology 2014;30:

CCS/CAIC/CSCS Position Statement on Revascularization Multi-vessel CAD. Teo et al, Canadian Journal of Cardiology 2014;30: CCS/CAIC/CSCS Position Statement on Revascularization Multi-vessel CAD Teo et al, Canadian Journal of Cardiology 2014;30: 1482-1491 Parallel Paper: Canadian Cardiovascular Society Guidelines for the Diagnosis

More information

Heart Failure Clinician Guide JANUARY 2018

Heart Failure Clinician Guide JANUARY 2018 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.

More information

Device Therapy for Heart Failure

Device Therapy for Heart Failure Device Therapy for Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics St Boniface General Hospital,

More information

Referral for Heart Transplantation - who and when?

Referral for Heart Transplantation - who and when? Transplant Referral for heart transplantation - who and when Sarah Fitzsimons Chairs: Kathy Ferrier & Richard Troughton Referral for Heart Transplantation - who and when? CSANZ June 2018 1 Introduction

More information

3/17/2014. NCDR-14 ICD Registry WS # 24 Case Scenarios Including Syndromes w/ Risk of Sudden Death. Objectives

3/17/2014. NCDR-14 ICD Registry WS # 24 Case Scenarios Including Syndromes w/ Risk of Sudden Death. Objectives NCDR-14 ICD Registry WS # 24 Case Scenarios Including Syndromes w/ Risk of Sudden Death Denise Pond BSN, RN The following relationships exist related to this presentation: No Disclosures Objectives Discuss

More information

2/17/2010. Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco

2/17/2010. Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco Modern Management of Patients with Stable Coronary Artery Disease Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco Scope of the Problem Prevalence of CAD: 17.6 million

More information

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012 IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the

More information

Heart Failure Clinician Guide JANUARY 2016

Heart Failure Clinician Guide JANUARY 2016 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.

More information

8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)

8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated) Professor Ralph Stewart Cardiologist Auckland City Hospital Green Lane Cardiovascular Research Unit Auckland Heart Group Fiona Stewart Cardiologist Green Lane Hospital National Women's Hospital Professor

More information

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology Cardiac evaluation for the noncardiac patient Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology Objectives! Review ACC / AHA guidelines as updated for 2009! Discuss new recommendations

More information

The Failing Heart in Primary Care

The Failing Heart in Primary Care The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and

More information

WHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine

WHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine WHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine Disclosures Data Safety Monitoring Board SOPRANO (J&J), EVALUATE-HF

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review

More information

Richard Grocott Mason

Richard Grocott Mason Richard Grocott Mason What to do with a 50 year old man with chest pain? Does the pain sound cardiac? Is this a possible acute coronary syndrome? Does patient have a previous cardiac history? Natural history

More information

Spinal Cord Stimulation Hani N. Sabbah, Ph.D., FACC, FCCP, FAHA Professor of Medicine Wayne State University & Director of Cardiovascular Research

Spinal Cord Stimulation Hani N. Sabbah, Ph.D., FACC, FCCP, FAHA Professor of Medicine Wayne State University & Director of Cardiovascular Research Spinal Cord Stimulation Hani N. Sabbah, Ph.D., FACC, FCCP, FAHA Professor of Medicine Wayne State University & Director of Cardiovascular Research Henry Ford Health System Disclosure Information ESC 2011

More information

Cardiogenic Shock. Carlos Cafri,, MD

Cardiogenic Shock. Carlos Cafri,, MD Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and

More information

Rebuilding and Reinvigorating Cardiac Rehabilitation in 2018

Rebuilding and Reinvigorating Cardiac Rehabilitation in 2018 Rebuilding and Reinvigorating Cardiac Rehabilitation in 2018 Pam R. Taub MD, FACC Director of Step Family Cardiac Wellness and Rehabilitation Center Associate Professor of Medicine UC San Diego Health

More information

InterQual Care Planning SIM plus Criteria 2014 Clinical Revisions

InterQual Care Planning SIM plus Criteria 2014 Clinical Revisions InterQual Care Planning SIM plus Criteria 2014 Clinical Revisions The Clinical Revisions provide details of changes to InterQual Clinical Criteria. They do not provide information on changes made to CareEnhance

More information

Guideline-Directed Medical Therapy

Guideline-Directed Medical Therapy Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in

More information

Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know

Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Steven J. Kalbfleisch, M.D. Medical Director Electrophysiology Laboratory Ross Heart Hospital Wexner Medical Center Sudden

More information

CRT Vs RV Pacing Benefits

CRT Vs RV Pacing Benefits CRT-P & CRT-D Indications According to Guidelines are Guidelines Fully Adopted? Salama H. Omar M.D. Prof. Critical Care Medicine, Cairo University CRT Vs RV Pacing Benefits 1 Benefit of Upgrade CTR-P &

More information

2016 Update to Heart Failure Clinical Practice Guidelines

2016 Update to Heart Failure Clinical Practice Guidelines 2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes

More information

Therapeutic Targets and Interventions

Therapeutic Targets and Interventions Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium

More information

Summary Protocol ISRCTN / NCT REVIVED-BCIS2 Summary protocol version 4, May 2015 Page 1 of 6

Summary Protocol ISRCTN / NCT REVIVED-BCIS2 Summary protocol version 4, May 2015 Page 1 of 6 Summary Protocol REVIVED-BCIS2 Summary protocol version 4, May 2015 Page 1 of 6 Background: Epidemiology In 2002, it was estimated that approximately 900,000 individuals in the United Kingdom had a diagnosis

More information

Form 4: Coronary Evaluation

Form 4: Coronary Evaluation Patient Details Hidden Show Show/Hide Annotations Form : Coronary Evaluation Print this Form t Started Date of Coronary Evaluation Coronary Evaluation Indication for Coronary Evaluation Check only one.

More information

Form 4: Coronary Evaluation

Form 4: Coronary Evaluation Form : Coronary Evaluation Print this Form t Started Date of Coronary Evaluation Coronary Evaluation Indication for Coronary Evaluation Check only one. Angio NOT DONE: n invasive test performed Followup

More information

Ventricular Arrhythmias

Ventricular Arrhythmias Presenting your most challenging cases Venice Arrhythmias Ventricular Arrhythmias Gioia Turitto, MD Presenter Disclosure Information A questionable indication for CRT-D in a patient with VT after successful

More information

Role of echocardiography in the assessment of ischemic heart disease 분당서울대학교병원윤연이

Role of echocardiography in the assessment of ischemic heart disease 분당서울대학교병원윤연이 Role of echocardiography in the assessment of ischemic heart disease 분당서울대학교병원윤연이 Outline Evaluation of Chest pain Evaluation of MI complications Prediction of Outcomes Evaluation of Chest pain Evaluation

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

FFR in Multivessel Disease

FFR in Multivessel Disease FFR in Multivessel Disease April, 26 2013 Coronary Physiology in the Catheterization Laboratory Location: European Heart House, Nice, France Pim A.L. Tonino, MD, PhD Hartcentrum, Eindhoven, the Netherlands

More information

E/Ea is NOT an essential estimator of LV filling pressures

E/Ea is NOT an essential estimator of LV filling pressures Euroecho Kopenhagen Echo in Resynchronization in 2010 E/Ea is NOT an essential estimator of LV filling pressures Wilfried Mullens, MD, PhD December 10, 2010 Ziekenhuis Oost Limburg Genk University Hasselt

More information

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center

More information

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G. Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center

More information

Summary, conclusions and future perspectives

Summary, conclusions and future perspectives Summary, conclusions and future perspectives Summary The general introduction (Chapter 1) of this thesis describes aspects of sudden cardiac death (SCD), ventricular arrhythmias, substrates for ventricular

More information

Pearls & Pitfalls in nuclear cardiology

Pearls & Pitfalls in nuclear cardiology Pearls & Pitfalls in nuclear cardiology Maythinee Chantadisai, MD., NM physician Division of Nuclear Medicine, Department of radiology, KCMH Principle of myocardial perfusion imaging (MPI) Radiotracer

More information

Congestive Heart Failure or Heart Failure

Congestive Heart Failure or Heart Failure Congestive Heart Failure or Heart Failure Dr Hitesh Patel Ascot Cardiology Group Heart Failure Workshop April, 2014 Question One What is the difference between congestive heart failure and heart failure?

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter

More information

Congestive Heart Failure: Outpatient Management

Congestive Heart Failure: Outpatient Management The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy

More information

Advanced Heart Failure Management. Dr Andrew Hannah Consultant Cardiologist Aberdeen Royal Infirmary

Advanced Heart Failure Management. Dr Andrew Hannah Consultant Cardiologist Aberdeen Royal Infirmary Advanced Heart Failure Management Dr Andrew Hannah Consultant Cardiologist Aberdeen Royal Infirmary Grading of heart failure Mr WY age 73 3/12 dyspnoea, fatigue and some ankle oedema PMH: hypertension

More information

Coronary Artery Disease: Revascularization (Teacher s Guide)

Coronary Artery Disease: Revascularization (Teacher s Guide) Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention

More information

APPENDIX F: CASE REPORT FORM

APPENDIX F: CASE REPORT FORM APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more

More information

Coronary Revascularization for Severe LV Dysfunction Is s. Is the concept of viability testing still viable?

Coronary Revascularization for Severe LV Dysfunction Is s. Is the concept of viability testing still viable? Coronary Revascularization for Severe LV Dysfunction Is s Is the concept of viability testing still viable? Banff 2017 2015 MFMER 3492638-7 Prognosis of Patients With LV Dysfunction and CAD Major determinants

More information

STEMI ST Elevation Myocardial Infarction

STEMI ST Elevation Myocardial Infarction STEMI ST Elevation Myocardial Infarction Breakout Session One Moderators: Quinn Capers IV, MD and Scott M. Lilly, MD, PhD Cases Presented by: Umair S. Ahmad, MD 1 Outline 1. Multivessel Revascularization

More information

Theme - Women and Heart Failure

Theme - Women and Heart Failure HeFSSA Practitioners Program 2015 Theme - Women and Heart Failure 08:00-08:20 Registration & Breakfast 08:20-08:25 Welcome and Thank You to Sponsors 08:25-08:30 HeFSSA smartphone patient app (video) 08:30-09:15

More information

Coronary Heart Disease. Iqbal Malik

Coronary Heart Disease. Iqbal Malik Coronary Heart Disease Iqbal Malik Pathophysiology IHD Case chest pain Question -interactive What is the result of the exercise test? 1. negative 2. positive 3. equivocal 4. other Q2 answer STEMI! What

More information

The role of CPX testing in the rehabilitation of cardiac patients.

The role of CPX testing in the rehabilitation of cardiac patients. Cardiopulmonary exercise testing (CPX) for comprehensive cardiac evaluations The role of CPX testing in the rehabilitation of cardiac patients. Viviane M Conraads, MD, PhD Department of Cardiology Cardiac

More information

Cases in Stress Echo DISCLOSURE

Cases in Stress Echo DISCLOSURE Cases in Stress Echo Susan Wilansky, MD, FRCP(C), FACC, FASE Mayo Clinic, AZ DISCLOSURE Relevant Financial Relationship(s) None Off Label Usage None 1 Exercise Testing in Patients with HCM (Class IIa)

More information

Effects of heart rate reduction with ivabradine on left ventricular remodeling and function:

Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography

More information

CABG alone. It s enough? / Μόνο η αορτοστεφανιαία παράκαμψη είναι αρκετή;

CABG alone. It s enough? / Μόνο η αορτοστεφανιαία παράκαμψη είναι αρκετή; LV Aneurysm and VSD in Ischaemic Heart Failure / Στεφανιαία νόσος, ανεύρυσμα αριστεράς κοιλίας και VSD CABG alone. It s enough? / Μόνο η αορτοστεφανιαία παράκαμψη είναι αρκετή; THEODOROS KARAISKOS CONSULTANT

More information

ESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309

ESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309 ESC Guidelines Update 2008 ESC Guidelines Heart failure update 2008 For internal training purpose. 0 Agenda Introduction Classes of recommendations Level of evidence Treatment algorithm Changes to ESC

More information

New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD

New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD Professor of Medicine, Cell Biology, Radiology and Surgery Director, The Howard Gilman Institute for Heart Valve Disease and the Schiavone

More information

Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies

Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern

More information

Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy

Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS

More information

Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh

Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention

More information

MADIT Studies: CRT in the Non-LBBB Patient and Other Findings. Arthur J. Moss, MD

MADIT Studies: CRT in the Non-LBBB Patient and Other Findings. Arthur J. Moss, MD MADIT Studies: CRT in the Non-LBBB Patient and Other Findings Arthur J. Moss, MD University of Rochester Medical Cntr. Rochester, NY 13 th Annual New Frontiers in Heart Failure Rx NYC, NY January 26, 2013

More information

Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines

Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland Conflict of Interests No conflict

More information

Zachary I. Hodes, M.D., Ph.D., F.A.C.C.

Zachary I. Hodes, M.D., Ph.D., F.A.C.C. Zachary I. Hodes, M.D., Ph.D., F.A.C.C. Disclamer: I personally have no financial relationship with any company mentioned today. The Care Group, LLC does have a contract with Cardium to participate in

More information

CRT-P or CRT-D From North Alberta to Nairobi

CRT-P or CRT-D From North Alberta to Nairobi CRT-P or CRT-D From North Alberta to Nairobi Dr Mzee Ngunga Aga Khan University Hospital Nairobi KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web:

More information

AF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management

AF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management AF in the ER: Common Scenarios Atrial fibrillation is a common problem with a wide spectrum of presentations. Below are five common emergency room scenarios and the management strategies for each. Evan

More information

PVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D.

PVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D. PVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D. Cardiologist and Electrophysiologist No conflict of interest related to this presentation Objectives 1. PVCs are benign. What is the Evidence?

More information

Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm

Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm Guy Amit, MD, MPH Soroka University Medical Center Ben-Gurion University of the Negev Beer-Sheva, Israel Disclosures Consultant:

More information

Congestive Heart Failure

Congestive Heart Failure Congestive Heart Failure Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology findings from the Heart Failure and A Controlled Trial Investigating Outcomes

More information